A miRNome analysis of drug-free manic psychotic bipolar patients versus healthy controls.
Biomarkers
Bipolar disorder (BD)
Epigenetics
Metabolism
Psychotic symptoms
miRNA
Journal
European archives of psychiatry and clinical neuroscience
ISSN: 1433-8491
Titre abrégé: Eur Arch Psychiatry Clin Neurosci
Pays: Germany
ID NLM: 9103030
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
11
02
2019
accepted:
07
08
2019
pubmed:
20
8
2019
medline:
29
6
2021
entrez:
19
8
2019
Statut:
ppublish
Résumé
The lifetime presence of psychotic symptoms is associated with more clinical severity, poorer outcome and biological changes in patients affected by bipolar disorder (BD). Epigenetic mechanisms have been evoked to explain the onset of psychotic symptoms in BD as well as the associated biological changes. The main objective of the present study was to evaluate the expression profiles of circulating microRNAs (miRNAs) in drug-free manic psychotic bipolar patients versus healthy controls (HC), to identify possible non-invasive molecular markers of the disorder. 15 drug-free manic psychotic bipolar patients and 9 HC were enrolled and 800 miRNAs expression profile was measured by Nanostring nCounter technology on plasma samples and validated through qPCR. Overall, twelve miRNAs showed a significantly altered expression between the two groups (p < 0.05). Functional annotation of predicted miRNAs targets by MultiMIR R tool showed repression in bipolar patients of genes with a role in neurodevelopment and neurogenesis, and upregulation of genes involved in metabolism regulation. We identified a signature of circulating miRNA characteristic of manic psychotic bipolar patients, suggesting a possible role in neurodevelopment and metabolic processes regulation.
Identifiants
pubmed: 31422452
doi: 10.1007/s00406-019-01057-2
pii: 10.1007/s00406-019-01057-2
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
893-900Références
Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, Viana MC, Andrade LH, Hu C, Karam EG, Ladea M (2011) Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68:241–251. https://doi.org/10.1001/archgenpsychiatry.2011.12
doi: 10.1001/archgenpsychiatry.2011.12
pubmed: 21383262
pmcid: 3486639
Altamura AC, Serati M, Buoli M (2015) Is duration of illness really influencing outcome in major psychoses? Nord J Psychiatry 69:403–417. https://doi.org/10.3109/08039488.2014.990919
doi: 10.3109/08039488.2014.990919
pubmed: 25768662
Altamura AC, Buoli M, Caldiroli A, Caron L, Cumerlato Melter C, Dobrea C, Cigliobianco M, Quarantini FZ (2015) Misdiagnosis, duration of untreated illness (DUI) and outcome in bipolar patients with psychotic symptoms: a naturalistic study. J Affect Disord 182:70–75. https://doi.org/10.1016/j.jad.2015.04.024
doi: 10.1016/j.jad.2015.04.024
pubmed: 25978716
Baldessarini RJ, Tondo L, Vazquez GH, Undurraga J, Bolzani L, Yildiz A, Yildiz A, Khalsa HM, Lai M, Lepri B, Lolich M, Maffei PM (2012) Age at onset versus family history and clinical outcomes in 1665 international bipolar-I disorder patients. World Psychiatry 11:40–46. https://doi.org/10.1016/j.wpsyc.2012.01.006
doi: 10.1016/j.wpsyc.2012.01.006
pubmed: 22295008
pmcid: 3266753
Buoli M, Serati M, Altamura AC (2017) Biological aspects and candidate biomarkers for rapid-cycling in bipolar disorder: a systematic review. Psychiatry Res 258:565–575. https://doi.org/10.1016/j.psychres.2017.08.059
doi: 10.1016/j.psychres.2017.08.059
pubmed: 28864122
Dell’Osso B, Camuri G, Cremaschi L, Dobrea C, Buoli M, Ketter TA, Altamura AC (2017) Lifetime presence of psychotic symptoms in bipolar disorder is associated with less favorable socio-demographic and certain clinical features. Compr Psychiatry 76:169–176. https://doi.org/10.1016/j.comppsych.2017.04.005
doi: 10.1016/j.comppsych.2017.04.005
pubmed: 28531646
van Rossum I, Haro JM, Tenback D, Boomsma M, Goetz I, Vieta E, van Os J, Advisory Board EMBLEM (2008) Stability and treatment outcome of distinct classes of mania. Eur Psychiatry 23:360–367. https://doi.org/10.1016/j.eurpsy.2008.02.005
doi: 10.1016/j.eurpsy.2008.02.005
pubmed: 18434101
Buoli M, Caldiroli A, Cumerlato Melter C, Serati M, de Nijs J, Altamura AC (2016) Biological aspects and candidate biomarkers for psychotic bipolar disorder: a systematic review. Psychiatry Clin Neurosci 70:227–244. https://doi.org/10.1111/pcn.12386
doi: 10.1111/pcn.12386
pubmed: 26969211
Fries GR, Carvalho AF, Quevedo J (2018) The miRNome of bipolar disorder. J Affect Disord 233:110–116. https://doi.org/10.1016/j.jad.2017.09.025
doi: 10.1016/j.jad.2017.09.025
pubmed: 28969861
Lopez JP, Kos A, Turecki G (2018) Major depression and its treatment: microRNAs as peripheral biomarkers of diagnosis and treatment response. Curr Opin Psychiatry 31:7–16. https://doi.org/10.1097/YCO.0000000000000379
doi: 10.1097/YCO.0000000000000379
pubmed: 29076893
Kumar S, Vijayan M, Bhatti JS, Reddy PH (2017) MicroRNAs as peripheral biomarkers in aging and age-related diseases. Prog Mol Biol Transl Sci 146:47–94. https://doi.org/10.1016/bs.pmbts.2016.12.013
doi: 10.1016/bs.pmbts.2016.12.013
pubmed: 28253991
Sun P, Liu DZ, Jickling GC, Sharp FR, Yin KJ (2018) MicroRNA-based therapeutics in central nervous system injuries. J Cereb Blood Flow Metab 38:1125–1148. https://doi.org/10.1177/0271678X18773871
doi: 10.1177/0271678X18773871
pubmed: 29708005
pmcid: 6434449
McNeill E, Van Vactor D (2012) MicroRNAs shape the neuronal landscape. Neuron 75:363–379. https://doi.org/10.1016/j.neuron.2012.07.005
doi: 10.1016/j.neuron.2012.07.005
pubmed: 22884321
pmcid: 3441179
Narahari A, Hussain M, Sreeram V (2017) MicroRNAs as biomarkers for psychiatric conditions: a review of current research. Innov Clin Neurosci 14:53–55
pubmed: 28386521
pmcid: 5373795
Chen H, Wang N, Burmeister M, McInnis MG (2009) MicroRNA expression changes in lymphoblastoid cell lines in response to lithium treatment. Int J Neuropsychopharmacol 12:975–981. https://doi.org/10.1017/S1461145709000029
doi: 10.1017/S1461145709000029
pubmed: 19254429
pmcid: 3216398
Rong H, Liu TB, Yang KJ, Yang HC, Wu DH, Liao CP, Hong F, Yang HZ, Wan F, Ye XY, Xu D (2011) MicroRNA-134 plasma levels before and after treatment for bipolar mania. J Psychiatr Res 45:92–95. https://doi.org/10.1016/j.jpsychires.2010.04.028
doi: 10.1016/j.jpsychires.2010.04.028
pubmed: 20546789
Walker RM, Rybka J, Anderson SM, Torrance HS, Boxall R, Sussmann JE, Porteous DJ, McIntosh AM, Evans KL (2015) Preliminary investigation of miRNA expression in individuals at high familial risk of bipolar disorder. J Psychiatr Res 62:48–55. https://doi.org/10.1016/j.jpsychires.2015.01.006
doi: 10.1016/j.jpsychires.2015.01.006
pubmed: 25708817
pmcid: 4379383
Buoli M, Serati M, Grassi S, Pergoli L, Cantone L, Altamura AC, Bollati V (2018) The role of clock genes in the etiology of major depressive disorder. J Affect Disord 234:351–357. https://doi.org/10.1016/j.jad.2017.11.015
doi: 10.1016/j.jad.2017.11.015
pubmed: 29128257
Wang H, Horbinski C, Wu H, Liu Y, Sheng S, Liu J, Liu J, Weiss H, Stromberg AJ, Wang C (2016) NanoStringDiff: a novel statistical method for differential expression analysis based on NanoString nCounter data. Nucleic Acids Res 44:e151. https://doi.org/10.1093/nar/gkw677
doi: 10.1093/nar/gkw677
pubmed: 27471031
pmcid: 5175344
First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured clinical interview for DSM-IV-TR Axis I disorders, research version, patient edition (SCID-I/P). Biometrics Research, New York State Psychiatric Institute, New York
Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psycol Rep 10:799
doi: 10.2466/pr0.1962.10.3.799
Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiat 133:429–435
doi: 10.1192/bjp.133.5.429
Bourin MS, Severus E, Schronen JP, Gass P, Szamosi J, Eriksson H, Chandrashekar H (2014) Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study. Int J Bipolar Disord 2:14. https://doi.org/10.1186/s40345-014-0014-9
doi: 10.1186/s40345-014-0014-9
pubmed: 25505693
pmcid: 4224669
Davies G et al (2008) Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nat Commun 9:2098. https://doi.org/10.1038/s41467-018-04362-x
doi: 10.1038/s41467-018-04362-x
Galimberti D, Villa C, Fenoglio C, Serpente M, Ghezzi L, Cioffi SM, Arighi A, Fumagalli G, Scarpini E (2014) Circulating miRNAs as potential biomarkers in Alzheimer’s disease. J Alzheimers Dis 42:1261–1267. https://doi.org/10.3233/JAD-140756
doi: 10.3233/JAD-140756
pubmed: 25024331
Yuan H, Mischoulon D, Fava M, Otto MW (2018) Circulating microRNAs as biomarkers for depression: many candidates, few finalists. J Affect Disord 233:68–78. https://doi.org/10.1016/j.jad.2017.06.058
doi: 10.1016/j.jad.2017.06.058
pubmed: 28673667
Geaghan M, Cairns MJ (2015) MicroRNA and posttranscriptional dysregulation in psychiatry. Biol Psychiatry 78:231–239. https://doi.org/10.1016/j.biopsych.2014.12.009
doi: 10.1016/j.biopsych.2014.12.009
pubmed: 25636176
Buoli M, Dell’Osso B, Caldiroli A, Carnevali GS, Serati M, Suppes T, Ketter TA, Altamura AC (2017) Obesity and obstetric complications are associated with rapid-cycling in Italian patients with bipolar disorder. J Affect Disord 208:278–283. https://doi.org/10.1016/j.jad.2016.10.010
doi: 10.1016/j.jad.2016.10.010
pubmed: 27794251
Fagiolini A, Chengappa KN, Soreca I, Chang J (2008) Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs 22:655–669
doi: 10.2165/00023210-200822080-00004
Altamura AC, Buoli M, Pozzoli S (2014) Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia. Psychiatry Clin Neurosci 68:21–36. https://doi.org/10.1111/pcn.12089
doi: 10.1111/pcn.12089
pubmed: 24102953
Hibar DP, Westlye LT, Doan NT, Jahanshad N, Cheung JW, Ching CRK et al (2018) Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group. Mol Psychiatry 23:932–942. https://doi.org/10.1038/mp.2017.73
doi: 10.1038/mp.2017.73
pubmed: 28461699
Huang Z (2009) Molecular regulation of neuronal migration during neocortical development. Mol Cell Neurosci 42:11–22. https://doi.org/10.1016/j.mcn.2009.06.003
doi: 10.1016/j.mcn.2009.06.003
pubmed: 19523518
Uribe E, Wix R (2012) Neuronal migration, apoptosis and bipolar disorder. Rev Psiquiatr Salud Ment 5:127–133. https://doi.org/10.1016/j.rpsmen.2011.11.003
doi: 10.1016/j.rpsmen.2011.11.003
pubmed: 22854584
Muñoz-Estrada J, Benítez-King G, Berlanga C, Meza I (2015) Altered subcellular distribution of the 75-kDa DISC1 isoform, cAMP accumulation, and decreased neuronal migration in schizophrenia and bipolar disorder: implications for neurodevelopment. CNS Neurosci Ther 21:446–453. https://doi.org/10.1111/cns.12377
doi: 10.1111/cns.12377
pubmed: 25620115
pmcid: 6495214
Schubert KO, Föcking M, Prehn JH, Cotter DR (2012) Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder? Mol Psychiatry 17:669–681. https://doi.org/10.1038/mp.2011.123
doi: 10.1038/mp.2011.123
pubmed: 21986877
Hajek T, McIntyre R, Alda M (2016) Bipolar disorders, type 2 diabetes mellitus, and the brain. Curr Opin Psychiatry 29:1–6. https://doi.org/10.1097/YCO.0000000000000215
doi: 10.1097/YCO.0000000000000215
pubmed: 26575297
Wulsin LR, Blom TJ, Durling M, Welge JA, DelBello MP, Adler CM, McNamara RK, Strakowski SM (2018) Cardiometabolic risks and omega-3 index in recent-onset bipolar I disorder. Bipolar Disord 20:658–665. https://doi.org/10.1111/bdi.12633
doi: 10.1111/bdi.12633
pubmed: 29479787
Vancampfort D, Mitchell AJ, De Hert M, Sienaert P, Probst M, Buys R, Stubbs B (2015) Prevalence and predictors of type 2 diabetes mellitus in people with bipolar disorder: a systematic review and meta-analysis. J Clin Psychiatry 76:1490–1499. https://doi.org/10.4088/JCP.14r09635
doi: 10.4088/JCP.14r09635
pubmed: 26214054
Enger C, Jones ME, Kryzhanovskaya L, Doherty M, McAfee AT (2013) Risk of developing diabetes and dyslipidemia among adolescents with bipolar disorder or schizophrenia. Int J Adolesc Med Health 25:3–11. https://doi.org/10.1515/ijamh-2013-0002
doi: 10.1515/ijamh-2013-0002
pubmed: 23337048